Browsing by Author "Aguiar, S"

Now showing 1 - 4 of 4

Impact of COVID-19 in pediatric oncology care in Latin America during the first year of the pandemic
(John Wiley and Sons Inc, 2022) Villanueva, G; Sampor, C; Palma, J; Villarroel, M; Valencia, D; Lombardi, MG; Garcia, WG; Caceres, EL; Sobrero, V; Garcia, L; Cabrera, V; Maza, I; Velasquez,T; Ugaz, C; Vasquez, JM; Coronado, RD; Gonzalez, N; Aguiar, S; Dabezies A; Moreno, F; Sardinas, S; Gamboa, Y; Maradiegue, E; Fu, L; Gassant, P; Moreno, K; Gonzales, O; Schelotto, M; Luna-Fineman, S; Antoneli, CG; Fuentes-Alabi, S; Luciani, S; Cappellano, A; Chantada, G; Vasquez, L
Background: The ongoing coronavirus 2019 disease (COVID-19) pandemic strained medical systems worldwide. We report on the impact on pediatric oncology care in Latin American (LATAM) during its first year. Method: Four cross-sectional surveys were electronically distributed among pediatric onco-hematologists in April/June/October 2020, and April/2021 through the Latin American Society of Pediatric Oncology (SLAOP) email list and St Jude Global regional partners. Results: Four hundred fifty-three pediatric onco-hematologists from 20 countries responded to the first survey, with subsequent surveys response rates above 85%. More than 95% of participants reported that treatment continued without interruption for new and active ongoing patients, though with disruptions in treatment availability. During the first three surveys, respondents reported suspensions of outpatient procedures (54.2%), a decrease in oncologic surgeries (43.6%), radiotherapy (28.4%), stem cell transplants (SCT) (69.3%), and surveillance consultations (81.2%). Logistic regression analysis showed that at the beginning of the first wave, participants from countries with healthcare expenditure below 7% were more likely to report a decrease in outpatient procedures (odds ratio [OR]: 1.84, 95% CI: 1.19–2.8), surgeries (OR: 3, 95% CI: 1.9–4.6) and radiotherapy (OR: 6, 95% CI: 3.5–10.4). Suspension of surveillance consultations was higher in countries with COVID-19 case fatality rates above 2% (OR: 3, 95% CI: 1.4–6.2) and SCT suspensions in countries with COVID-19 incidence rate above 100 cases per 100,000 (OR: 3.48, 95% CI: 1.6–7.45). Paradoxically, at the beginning of the second wave with COVID-19 cases rising exponentially, most participants reported improvements in cancer services availability. Conclusion: Our data show the medium-term collateral effects of the pandemic on pediatric oncology care in LATAM, which might help delineate oncology care delivery amid current and future challenges posed by the pandemic. © 2022 Wiley Periodicals LLC.
SELNET clinical practice guidelines for bone sarcoma
(Elsevier Ireland Ltd, 2022) Blay, JY; Palmerini, E; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Carvajal-Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, Víctor; Chacón, M; Clara-Altamirano, MA; Collini, P; Correa-Genoroso, R; Costa, FD; Cuellar, M; dei Tos, AP; Dominguez-Malagon, HR; Donati, DM; Dufresne, A; Eriksson, M; Farias-Loza M; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gerderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Hindi, N; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes, A; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Maki, RG; Martinez-Said, H; Martinez-Tlahuel, JL; Mello, CA; Morales-Pérez, JM; Moura, DS; Nakagawa, SA; Nascimento, AG; Ortiz-Cruz, EJ; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Santos, TG; Scotlandi, K; Soulé, T; Stacchiotti, S; Valverde, CM; Waisberg, F; Zamora-Estrada, E; Martin-Broto, J
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context. © 2022 The Authors
SELNET clinical practice guidelines for bone sarcoma
(Elsevier Ireland Ltd, 2022) Blay, JY; Palmerini, E; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Chs, CS; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden, V; Chacón, M; Clara-Altamirano, MA; Collini, P; Correa Genoroso, R; Costa, FD; Cuellar, M; Dei Tos, AP; Dominguez Malagon, HR; Donati, DM; Dufresne, A; Eriksson, M; Farias-Loza, M; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gerderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Hindi, N; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes, A; Lopes David, BB; Lopez-Pousa, A; Lutter, G; Maki, RG; Martinez-Said, H; Martinez-Tlahuel, JL; Mello, CA; Morales Pérez, JM; Moura, DS; Nakagawa, SA; Nascimento, AG; Ortiz-Cruz, EJ; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Santos, TG; Scotlandi, K; Mlg S, Soulé T; Stacchiotti, S; Valverde, CM; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context.
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(W.B. Saunders Ltd, 2022) Blay, JY; Hindi, N; Bollard, J; Aguiar, S; Angel, M; Araya, B; Badilla, R; Bernabeu, D; Campos, F; Caro-Sánchez, CHS; Carvajal, B; Carvajal Montoya, A; Casavilca-Zambrano, S; Castro-Oliden V; Chacón, M; Clara, M; Collini, P; Correa-Genoroso, R; Costa, FD; Cuellar, M; dei Tos, AP; Dominguez Malagon, HR; Donati, A; Dufresne, A; Eriksson, M; Farias-Loza, M; Fernandez, P; Frezza, AM; Frisoni, T; Garcia-Ortega, DY; Gelderblom, H; Gouin, F; Gómez-Mateo, MC; Gronchi, A; Haro, J; Huanca, L; Jimenez, N; Karanian, M; Kasper, B; Lopes David, BB; Lopez-Pousa, A; Lutter, G|Martinez-Said, H; Martinez-Tlahuel, J; Mello, CA; Morales-Pérez, JM; Moura-David, S; Nascimento, AG; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Pfluger, Y; Provenzano, S; Righi, A; Rodriguez, A; Salas, R; Santos, TTG; Scotlandi, K; Soule, T; Stacchiotti, S; Valverde, C; Waisberg, F; Zamora Estrada, E; Martin-Broto, J
Soft tissue sarcoma (STS) is a heterogeneous group of neoplasms, encompassing > 80 different histologic subtypes. Approximately three quarter of sarcoma arise from soft-tissue, about 15% are gastrointestinal stromal tumours (GISTs) and bone sarcoma represent the remaining 10%. The current guidelines will focus on soft-tissue and GIST, excluding Kaposi sarcoma and non-pleomorphic rhabdomyosarcoma. Bone sarcomas are covered in a different paper.